Madopar Hbs

Levodopa and Benserazide, the active ingredients in Madopar Hbs, are antiparkinson agents presented as an oral tablet for oral use. They treat Parkinson's disease and Parkinsonian syndrome by restoring dopamine levels in the brain and improving motor control.

GNH USA supplies Madopar Hbs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Madopar Hbs is used within the antiparkinson therapeutic pathway to manage motor symptoms of Parkinsonian disorders.

- Parkinson's disease: improves bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates motor impairment caused by dopamine deficiency. - Motor fluctuations in Parkinson's disease: reduces OFF periods and enhances overall daily functioning.

Adverse reactions may occur with any antiparkinson medication and should be monitored during therapy.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Severe hypotension or syncope - Hallucinations or psychosis - Cardiac arrhythmias - Neuroleptic malignant syndrome - Severe allergic reactions (e.g., rash, angioedema)

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for safety concerns.

- Renal impairment: adjust dose and monitor renal function. - Hepatic impairment: use caution, especially in severe liver disease. - Cardiovascular disease: watch for orthostatic hypotension and arrhythmias. - Psychiatric disorders: monitor for hallucinations, confusion, or worsening psychosis. - Pregnancy and lactation: use only if potential benefit outweighs risk; data are limited. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Levodopa/benserazide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Pyridoxine (vitamin B6) alone: accelerates peripheral levodopa metabolism. - Antipsychotics that block dopamine receptors (e.g., haloperidol): markedly reduce therapeutic effect. - High‑protein meals taken simultaneously: compete for transport across the blood‑brain barrier.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive hypotensive effect. - SSRIs or SNRIs: may increase risk of serotonin syndrome. - Other antiparkinson drugs (e.g., COMT inhibitors): may require dose adjustments. - Diuretics: monitor electrolytes and blood pressure.